Skip to main content
Staff Login
Username
*
Enter your The Contraceptive Pipeline Database username.
Password
*
Enter the password that accompanies your username.
Log in
Forgot password
Toggle navigation
Progering
Product Overview
Alternative Name:
Progesterone Vaginal Ring (PVR)
Development Status:
Limited Market Approval
Target:
Female
Mode:
Hormonal
Delivery Type:
Vaginal Ring
Duration Type:
Long-acting
Description:
A progesterone only 3-month vaginal ring, marketed specifically for breastfeeding women. Progesterone prevents resumption of ovulation and prolongs lactational amenorrhea. Given its short half-life orally, it is destroyed when ingested in mother's milk and there is no impact on the infant.
Updated date:
May 30, 2018
Vertical Tabs
Product Details
Active Pharmaceutical Ingredient (API):
progesterone
Inactive material:
Elastomer
Potential Multi-Purpose Technology (MPT):
No
Regimen:
One ring for 3 months
Duration:
3 months
Dose:
10 mg
Partner:
Population Council
,
Grunenthal
Status
Project Phase:
Post-development
Project Stage:
Regulatory
Began discovery in:
mid-1990'
Status Details:
Progering (developed by Population Council, CONRAD, UNFPA and Silesia) has been approved for use in Bolivia, Chile, Ecuador, Guatemala, Dominican Republic, El Salvador, Panama, and Peru.
Additional phase III study ongoing in India for submission to Government of India for approval. Additional acceptability studies ongoing in sub-Saharan Africa in preparation for introduction.
It is under evaluation at WHO for the Essential Medicine list and prequalification program at manufacturing site.
Programmatic Considerations
Considerations:
Clinical trials have shown high contraceptive efficacy and safety among lactating women; over 98.4% efficacy.
Does not require special infrastructure for storage when not inserted.
Additional Information
Additional Information:
Population Council Website
Download Product Report
